Funding Announcements

"With a vision to make AI accessible across various industries, we look forward to supporting Implement AI in accelerating the transformation of AI on a global scale. We are thrilled to be part of Piers’ and Aalok’s journey to make AI accessible to businesses of all shapes and sizes."

"We have the opportunity to become the go-to application for clinicians to access the information they need, where and when they need it, reducing the administrative burden and unlocking a happier and more productive workforce."

"For the super-large enterprises moving product all over the globe, transport procurement and management is a major expense both financially and in terms of time. Teams are often individually managing hundreds of carrier relationships, it truly has become an impossible task to do well. Third-party logistic (3PL) companies are inefficient and fail at promoting crucial strategic partnerships between shippers and their carriers. It’s a challenge in need of a solution, and today’s funding announcement is the next major step for us to be able to provide that solution."

"Open banking has laid the groundwork to reduce payment costs by creating the necessary conditions, but most A2A payment companies haven't been able to leverage this potential. At Volume, we've cracked the problem. We're solving the adoption challenges of account-to-account payments by focusing on the user experience for both businesses and consumers, offering a faster, more secure solution that puts both parties first. Our traction shows that pay-by-bank can be a scalable business model, and we're close to profitability with a clear product-market fit in cross-border payments. Like Stripe did with the shift from cash to card, we're leading the transition from debit cards to bank payments in open banking, while growing sustainably. If widely adopted, Volume could save businesses up to $44 billion per year."

"We are so excited to be taking the next step in our spin-out journey and want to sincerely thank all the investors and supporters who have helped us make it happen. Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible. This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work, and we look forward to using the funding to further develop our technology."